Shapely’s advertised price is not one all-inclusive bill. A prospective patient may encounter a first-month membership promotion, a separate medication price, insurance cost-sharing and a lab charge. The most important distinction is between paying for access to care and paying for the prescription itself. The injectable semaglutide offer starting at $99 per month and tirzepatide offer starting at $166 per month both require additional membership, and those starting prices belong to specific three-month packages rather than every monthly purchase.
This documentary review examines Shapely’s public materials consulted October 19, 2026, with an emphasis on the first payment, recurring costs and unresolved billing conditions. Shapely describes a telehealth weight-management service for adults in California, Florida, New York and Texas, combining clinical visits, dietitian access and prescription support. Its published prices are useful, but differences between insurance pages, incomplete package-payment terms and missing cancellation details make a personalized written quote particularly important before enrollment.
At a glance
- Self-pay membership
- Shapely advertises $49 for the first month of self-pay membership and a regular price of $99 per month; medication and labs are excluded.Sources: [5]
- Semaglutide injection packages
- Three-month starter and low-to-mid-dose refill packages are advertised at $99 per month, $297 total each; the high-dose package is $159 per month, $477 total. Membership is additional.Sources: [3]
- Tirzepatide injection packages
- The three-month starter package is $166 per month, $498 total; low-to-mid-dose refill is $199 per month, $597 total; high-dose is $279 per month, $837 total. Membership is additional.Sources: [7]
- Insurance pricing needs reconciliation
- The homepage promotes a $9 first membership month with insurance; the UnitedHealthcare page lists $49 per month plus applicable copays or deductibles, excluding medication.
- Documented service area
- Shapely says it currently serves adults age 18 and older in California, Florida, New York and Texas. Nationwide expansion is described as future availability.Sources: [5]
Start with the membership—not the drug headline
The self-pay membership block shows $99 per month with a $49 first-month offer, described as a $50 introductory saving. That is the care-access price, not a promise of medication for $49. Shapely explicitly excludes both prescriptions and labs from membership. Its terms identify the business as Zaghi Medical, Inc., doing business as Shapely. For budgeting, the practical starting point is a recurring membership line alongside a separate prescription line, with testing added when applicable.
The membership offering is more substantial than a prescription-request portal. Shapely lists monthly video visits with a weight-loss clinician, prescriptions when appropriate, help obtaining insurance coverage, assistance locating medication at local pharmacies, one-to-one dietitian access and unlimited support through chat and its app. Those are advertised services, not documented response-time guarantees. The sources do not establish how quickly a patient can obtain an initial appointment, receive a chat response or complete a coverage review.
A cellular-enabled scale is also advertised for use during the program, but it is not currently available when Aetna or Cigna is the primary insurance. That exception matters when comparing inclusions rather than just prices. The broader budgeting principle is explained in our guide to what a program price actually includes: an attractive membership fee is useful only when the separate expenses and material service restrictions are visible alongside it.
What the injectable price tables actually say
Shapely’s compounded injectable pages distinguish monthly purchases from three-month packages and separate lower-to-middle pricing categories from higher ones. These are commercial categories, not instructions for selecting a dose. The semaglutide headline of “as low as $99/month” corresponds to specified three-month packages. Tirzepatide’s $166 starting figure applies to its starter package; its low-to-mid-dose refill package costs more. In both cases, the page states that membership is required to access medication.
The table below preserves the advertised medication prices without treating monthly equivalents as the amount necessarily collected at checkout. The materials do not establish when package totals are charged. A three-month package also does not, by itself, establish the quantity dispensed, shipping schedule or a minimum membership commitment. Shapely advertises savings of up to 33% on three-month packages, but that is its commercial claim rather than an independently calculated saving for every patient.
Affirm and Klarna are listed as available, without the supplied pages explaining interest, eligibility or repayment terms. Their presence should not be read as either mandatory financing or a guaranteed installment option. Before choosing a package, request the amount due immediately, the next charge date and the medication presentation covered by the quote. Our explanation of monthly and prepaid billing helps separate a displayed monthly equivalent from a documented payment schedule.
| Purchase option | Semaglutide injection | Tirzepatide injection |
|---|---|---|
| Monthly, low-to-mid-dose category | $139/month | $249/month |
| Monthly, high-dose category | $179/month | $299/month |
| Three-month starter package | $99/month; $297 total | $166/month; $498 total |
| Three-month low-to-mid-dose refill | $99/month; $297 total | $199/month; $597 total |
| Three-month high-dose package | $159/month; $477 total | $279/month; $837 total |
Insurance adds a second set of price questions
The homepage advertises a $9 first membership month when paying with insurance. Separately, Shapely’s UnitedHealthcare page lists a $49 monthly membership plus applicable copays or deductibles, with medication excluded. The supplied documentation does not uniformly establish the price after the $9 promotion or show that the UnitedHealthcare figure applies to every insured patient. Those are different published offers that need reconciliation, not interchangeable descriptions of a single guaranteed rate.
Shapely explains that insurance-supported consultations can still leave the patient responsible for copays, deductibles and coinsurance. A membership fee remains for app access, chat, education, tracking tools and help locating medication. The company says it is in network with Medicare and most PPO plans, naming Aetna, Blue Shield and United among examples. These are provider assertions, not independently verified network findings, and acceptance of insurance for care does not establish coverage for a prescription.
For UnitedHealthcare, Shapely says medication coverage varies by plan and may require prior authorization or proof of medical necessity; it offers help completing those authorizations. The homepage describes commercial-insurance medication copays as typically $25 monthly, while warning they may be higher. Neither statement is a patient-specific quote. Our guide to insurance and self-pay questions can help organize separate confirmations for consultation benefits, membership charges and the pharmacy claim before money changes hands.
Medicare claims need their own written breakdown
The Medicare page uses “Co-pays only” and advertises care as low as $15 per month, or free with secondary insurance. That statement concerns the care offer; it is not an all-inclusive medication price. It also needs to be reconciled with the homepage’s broader explanation of ongoing membership fees and possible cost-sharing. A Medicare patient should ask which charges apply to their exact coverage arrangement rather than assume that one promotional phrase overrides every other pricing statement.
The same page says that, from July 1, 2026, eligible patients with Medicare Part D can access Wegovy, Zepbound and Foundayo for $50 monthly through a Medicare GLP-1 Bridge program. This review does not independently verify that program or its conditions. The claim must remain attributed to Shapely and limited to the stated eligibility, rather than presented as universal Medicare drug coverage or a guaranteed $50 prescription for anyone enrolling.
There is a material difference elsewhere on the site: the homepage describes Medicare coverage only for patients with diabetes, cardiovascular disease or obstructive sleep apnea, without mentioning the Bridge program. The consulted materials do not resolve that difference. The useful next step is a written explanation identifying the applicable coverage route, eligibility requirements, prescription charge, care cost-sharing and any membership fee. A dated program description is not enough to establish what a particular patient will owe.
The prescription route changes the remaining bill
Shapely’s catalogue lists Oral Wegovy, Ozempic and Wegovy under semaglutide, and Zepbound and Mounjaro under tirzepatide. It also lists Foundayo as orforglipron and Contrave as bupropion and naltrexone. Those catalogue descriptions document what Shapely markets; this review has not independently verified each product’s regulatory status or availability. “Insurance accepted” beside a listing does not establish that an individual plan covers that medicine, presentation or prescribed use.
For patients considering branded self-pay routes, Shapely says it can help access Wegovy through NovoCare and Zepbound through Lilly Direct, with possible discounts for eligible patients. It supplies no universal price for those routes in the evidence reviewed and explicitly disclaims affiliation with Novo Nordisk, Eli Lilly or their patient programs. Those offers therefore should not be substituted into the compounded injection price table or treated as discounts available to every member.
The compounded pages say these medications are self-pay only and are not reimbursed by insurance. Shapely describes personalized prescriptions based on an individual clinical evaluation and says it works exclusively with pharmacies it characterizes as state-licensed 503A and 503B compounding pharmacies. The consulted texts do not name those pharmacies or provide their licenses. The terms also recognize the patient’s option to request transmission of a prescription to a pharmacy of their choice; that does not establish identical pricing or availability through every pharmacy.
Labs and shipping: included items still have boundaries
Shapely strongly recommends recent labs before most weight-loss medications but says they are not required before most treatment starts. The homepage accepts results completed within six months before enrollment or offers to order testing. For uninsured patients, it advertises a flat $75 lab charge with an in-person blood draw at Labcorp. Membership does not include labs, and the statement that testing is typically covered by insurance should not be treated as a guarantee of no patient expense.
The Medicare page instead accepts labs completed within the preceding 12 months. Because the pages differ, a patient with existing results should ask which window applies before paying for another draw. This is a concrete cost uncertainty, not merely a wording issue: whether existing records are accepted may affect both an additional charge and the work needed before treatment. The documentation does not explain whether the different windows reflect distinct care pathways.
Both injectable pages advertise free two-day shipping, and the semaglutide page specifically includes shipping, syringes and alcohol pads. That does not make the treatment free or establish delivery two days after enrollment. Clinical review, prescribing and preparation are separate steps with no documented overall timetable here. Refrigeration methods, tracking and damaged-package remedies are also unspecified. FDA advises not using an injectable GLP-1 product that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy.
What happens between enrollment and ongoing care
Shapely says enrollment begins with insurance information and health goals so it can verify coverage, followed by a video consultation with an assigned clinician who personalizes the plan. Its documented current service area is limited to adults 18 and older in California, Florida, New York and Texas. Planned expansion to all 50 states is not current nationwide access. The supplied materials do not provide a complete clinical intake form or detailed provider-specific eligibility criteria.
A prescription is not guaranteed. The terms leave prescribing to professional judgment and exclude DEA-controlled or scheduled medications and certain other drugs with abuse potential. For people who are not good candidates for GLP-1 treatment, Shapely advertises alternative medications, lifestyle modification, continuous glucose monitoring and other tools. No complete price schedule for those alternatives is supplied. Paying for membership should therefore not be mistaken for buying a particular drug or securing a predetermined prescription.
There is also an unresolved responsibility issue in the terms: one passage refers to clinicians employed or contracted by Shapely, while another says Shapely does not employ, supervise or control the treating professionals. Patients can reasonably ask who provides care and handles clinical concerns. App and chat access are advertised, but response times are not established. The terms additionally warn that text messages and emails may be unencrypted, a relevant distinction when choosing how to communicate sensitive information.
Renewal and exit terms remain the largest budgeting gap
The supplied documentation does not establish automatic-renewal terms, cancellation procedures, refund eligibility, medication-return rules or early-exit treatment for three-month packages. The available terms text contains an omitted middle portion, so these gaps should not be described as proof that Shapely has no policies. They do mean this review cannot tell a reader how to stop future charges, whether an unused package balance is refundable or what happens if treatment changes after payment.
Before purchasing, request the membership renewal price, medication renewal price, charge dates, cancellation channel and any notice deadline. Ask separately what happens to already-paid medication and membership fees: stopping future billing and obtaining a refund are different questions. Our guide to cancellation and refunds explains that distinction. For Shapely specifically, the unanswered package-payment and financing terms make it especially important to retain the written quote and applicable terms rather than rely on a monthly headline.
Price also cannot resolve the clinical differences between products. FDA says compounded preparations are not FDA approved and lack its premarket review for safety, effectiveness and quality; nonapproval alone does not prove clinical inequivalence. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and state-licensed pharmacy. Shapely’s pharmacy-quality claims do not replace that context, and FDA approval applies to a specific product—not to a clinic or pharmacy.
Questions & answers
Does Shapely’s $49 first month include medication?
No. The $49 offer is the first month of self-pay membership, followed by the advertised regular $99 monthly membership price. Shapely explicitly excludes medication and labs. A prescription purchase, any applicable testing and the timing of package charges need separate confirmation. The compounded drug pages also state that membership is required, so their medication prices are not substitutes for the membership fee.
Can I buy tirzepatide for $166 every month?
The advertised $166 monthly equivalent applies to the three-month starter package, totaling $498, with membership additional. Shapely lists the three-month low-to-mid-dose refill at $199 per month, $597 total, and the high-dose package at $279 per month, $837 total. Its separate monthly options are $249 and $299 by category. The evidence does not establish when package totals are collected or guarantee eligibility for a particular package.
What should a UnitedHealthcare member confirm?
Ask Shapely to reconcile the homepage’s $9 first-month insurance promotion with the UnitedHealthcare page’s $49 monthly membership. Then confirm consultation cost-sharing and medication coverage separately. Shapely says prior authorization or proof of medical necessity may be required and offers assistance, but that assistance does not guarantee approval. The UnitedHealthcare membership price excludes medication, and the site’s typical $25 commercial-insurance drug copay is not a personalized benefit determination.
Will Shapely accept labs I already have?
Possibly. The homepage says it accepts labs completed within six months before enrollment, while the Medicare page gives a 12-month window. Ask which standard applies to your care pathway and whether your existing results are sufficient before arranging another draw. For patients without insurance, Shapely advertises a $75 flat-rate lab option requiring a visit to Labcorp; that charge is separate from membership.
Does free two-day shipping mean treatment arrives two days after signup?
No. The injectable pages advertise free two-day shipping, but do not establish the full time from enrollment through consultation, prescribing and medication preparation to arrival. The sources also do not specify cold-chain procedures or remedies for delivery problems. FDA advises against using injectable GLP-1 medication that arrives warm or insufficiently refrigerated; contact Shapely or the dispensing pharmacy to resolve that concern rather than relying on the shipping headline.
Is a three-month package refundable if my prescription changes?
The supplied materials do not answer that question. They list package prices but do not establish early-exit rules, medication returns or refund boundaries, and the available terms text is incomplete. Before paying, ask how a clinical change affects already-paid medication, future shipments and membership charges. Request cancellation instructions separately from refund terms; neither the package duration nor the availability of financing establishes a right to receive money back.
Our assessment
Shapely documents a meaningful care offering: monthly video visits, dietitian access, coverage assistance and multiple prescription routes. It also publishes useful medication price tables rather than only a starting figure. The limitation is that those figures do not produce a complete, dependable checkout or renewal total on their own. Membership remains separate, insured patients may face several kinds of cost-sharing, Medicare descriptions differ, and package collection and exit terms are unresolved in the consulted materials. A practical evaluation should therefore turn on a written, individualized breakdown of the first charge, subsequent membership and medication charges, testing, coverage conditions and cancellation/refund rules. Shapely’s pricing can be compared, but the lowest headline should not be treated as the entire cost of care.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.